Beta Bionics, Inc. announced on 30 August that it has secured $100m in series D equity funding, which will be used to commercialize its newly US Food and Drug Administration-cleared iLet artificial pancreas technology and to further develop and test the bi-hormonal bionic pancreas.
Sands Capital and Omega Funds co-led the financing, which participation from previous backers Soleus Capital, Eventide Asset Management LLC, Farallon...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?